Text Size

Long Term Cardiovascular Complications in Men With Obstructive Sleep Apnea

This study is currently recruiting participants.
Verified July 2012 by The University of Hong Kong
Sponsor:
Information provided by (Responsible Party):
Lam Jamie Chung Mei, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT01475682
First received: November 16, 2011
Last updated: July 3, 2012
Last verified: July 2012
History of Changes
  Purpose

Subjects with Obstructive Sleep Apnea (OSA) are at increased risk of developing cardiometabolic complications, and effective long-term nCPAP treatment significantly reduces the risk of cardiovascular morbidity and mortality.


Condition
Obstructive Sleep Apnea
Cardiovascular Diseases
Metabolic Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long Term Cardiovascular Complications in Men With Obstructive Sleep Apnea - Prospective 9 Years Follow-up Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by The University of Hong Kong:

Primary Outcome Measures:
  • Incidence of cardiometabolic complications [ Time Frame: 9 years ] [ Designated as safety issue: No ]
    167 subjects recruited from our previous "OSA and metabolic syndrome" (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point.


Secondary Outcome Measures:
  • Effects of CPAP treatment on cardiometabolic conditions [ Time Frame: 9 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 167
Study Start Date: November 2011
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
167 subjects recruited from our previous "OSA and metabolic syndrome" (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point.

Detailed Description:

  1. Primary outcome:

    Incidence of cardiometabolic diseases in subjects with OSA over 9 years.

  2. Secondary outcomes:

Effects of CPAP treatment on cardiometabolic conditions

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

167 subjects recruited from our previous "OSA and metabolic syndrome" (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point.

Criteria

Inclusion Criteria:

  • From previous cohort for reassessment.

Exclusion Criteria:

  • Unstable medical conditions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01475682

Contacts
Contact: Jamie C Lam, MD 852-22555906 lamcmj@hku.hk

Locations
Hong Kong
Queen Mary Hospital Recruiting
Hong Kong, Hong Kong
Contact: Jamie C Lam, MD     852-22555906     lamcmj@hku.hk    
Sponsors and Collaborators
The University of Hong Kong
Investigators
Principal Investigator: Jamie C Lam, MD The University of Hong Kong
  More Information

No publications provided

Responsible Party: Lam Jamie Chung Mei, Honorary Clinical Assistant Professor, The University of Hong Kong
ClinicalTrials.gov Identifier: NCT01475682     History of Changes
Other Study ID Numbers: UW 10-002
Study First Received: November 16, 2011
Last Updated: July 3, 2012
Health Authority: Hong Kong: Department of Health

Keywords provided by The University of Hong Kong:
Obstructive sleep apnea
cardiometabolic complications
Effects of CPAP treatment

Additional relevant MeSH terms:
Apnea
Cardiovascular Diseases
Metabolic Diseases
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
 Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases

ClinicalTrials.gov processed this record on May 21, 2013